Voronoi Past Earnings Performance
Past criteria checks 0/6
Voronoi's earnings have been declining at an average annual rate of -1.9%, while the Biotechs industry saw earnings growing at 7.7% annually. Revenues have been declining at an average rate of 83.4% per year.
Key information
-1.9%
Earnings growth rate
9.6%
EPS growth rate
| Biotechs Industry Growth | 11.7% |
| Revenue growth rate | -83.4% |
| Return on equity | -52.3% |
| Net Margin | n/a |
| Last Earnings Update | 30 Jun 2024 |
Recent past performance updates
Revenue & Expenses Breakdown
How Voronoi makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Jun 24 | 0 | -36,066 | 14,628 | 14,815 |
| 31 Mar 24 | 0 | -35,040 | 14,013 | 13,484 |
| 31 Dec 23 | 0 | -36,848 | 13,816 | 14,464 |
| 30 Sep 23 | 589 | -30,991 | 13,483 | 13,900 |
| 30 Jun 23 | 7,943 | -22,876 | 13,117 | 13,862 |
| 31 Mar 23 | 8,630 | -22,143 | 12,843 | 13,326 |
| 31 Dec 22 | 9,768 | -19,900 | 12,599 | 11,727 |
| 30 Sep 22 | 13,845 | -14,095 | 12,252 | 11,316 |
| 30 Jun 22 | 12,167 | -18,108 | 12,139 | 13,402 |
| 31 Mar 22 | 14,419 | -18,833 | 11,611 | 13,121 |
| 31 Dec 21 | 14,784 | -15,096 | 9,650 | 12,492 |
| 30 Sep 21 | 16,095 | -12,472 | 10,233 | 11,913 |
| 31 Dec 20 | 6,180 | -23,187 | 16,262 | 13,412 |
| 31 Dec 19 | 301 | -50,003 | 20,166 | 31,498 |
| 31 Dec 18 | 174 | -9,218 | 3,518 | 7,047 |
| 31 Dec 17 | 34 | -1,882 | 1,687 | 724 |
Quality Earnings: A310210 is currently unprofitable.
Growing Profit Margin: A310210 is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: A310210 is unprofitable, and losses have increased over the past 5 years at a rate of 1.9% per year.
Accelerating Growth: Unable to compare A310210's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: A310210 is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (18.8%).
Return on Equity
High ROE: A310210 has a negative Return on Equity (-52.27%), as it is currently unprofitable.